Patients with Metastatic NSCLC Benefit from Treatment for Depression

Share this content:

(ChemotherapyAdvisor) – In patients with newly diagnosed metastatic non–small-cell lung cancer (NSCLC), the presence of depression predicted worse survival; however, “the data do not support the hypothesis that treatment of depression mediated the observed survival benefit from early palliative care,” investigators reported in the Journal of Clinical Oncology online March 19.

“Nonetheless, a key finding in this analysis is that depression is clearly treatable in patients with metastatic NSCLC,” Pirl et al. from Massachusetts General Hospital Cancer Center, Boston, MA, noted. Previously, they observed in a randomized trial that early palliative care integrated with standard oncology care improved survival in patients (n=77) vs. those who received standard oncology care alone (n=74).

In a secondary analysis, they explored the hypothesis that this survival benefit resulted from improving depression, assessing depression at baseline and 12 weeks with the Patient Health Questionnaire-9 (PHQ-9), which was scored using the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, criteria for major depression syndrome. Depression response was considered ≥50% reduction in PHQ-9 scores at 12 weeks.

At baseline, 21 patients (14%) met the criteria for major depression syndrome, which significantly predicted worse survival (HR, 1.82; P=0.02). Those randomized to receive early palliative care had greater improvements in PHQ-9 scores at 12 weeks (P<0.001) and, among patients with major depression syndrome, greater rates of depression response at 12 weeks (P=0.04). However, improvement in PHQ-9 scores was not associated with improved survival.

“Although survival might be considered the ultimate end point in oncology, depression is a disabling illness associated with suffering and poor quality of life that warrants intervention regardless of the potential impact on survival. Early palliative care might represent another option for its treatment,” they noted.

Future studies should include repeated assessments of depression within the first 12 weeks. “Because 18% of these newly diagnosed patients will not be alive by 12 weeks, determining the trajectory of their depressive symptoms is critical.”


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs